West Pharmaceutical Services, Inc. (WST) to Distribute Quarterly Dividend of $0.22 on August 5th

Posted by Francis Steltz on Jul 27th, 2026

West Pharmaceutical Services, Inc. (NYSE:WST – Get Free Report) announced a quarterly dividend on Tuesday, July 21st. Stockholders of record on Wednesday, July 29th will be paid a dividend of 0.22 per share by the medical instruments supplier on Wednesday, August 5th. This represents a c) annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Wednesday, July 29th.

West Pharmaceutical Services has increased its dividend payment by an average of 0.1%annually over the last three years. West Pharmaceutical Services has a dividend payout ratio of 12.4% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect West Pharmaceutical Services to earn $9.79 per share next year, which means the company should continue to be able to cover its $0.88 annual dividend with an expected future payout ratio of 9.0%.

West Pharmaceutical Services Stock Up 0.1%

NYSE:WST opened at $328.61 on Monday. The firm has a market capitalization of $23.13 billion, a price-to-earnings ratio of 42.08, a PEG ratio of 2.56 and a beta of 1.16. West Pharmaceutical Services has a 1-year low of $223.83 and a 1-year high of $386.00. The company has a current ratio of 2.82, a quick ratio of 2.12 and a debt-to-equity ratio of 0.07. The business’s fifty day moving average price is $337.02 and its 200 day moving average price is $287.49.

West Pharmaceutical Services (NYSE:WST – Get Free Report) last posted its quarterly earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.08 by $0.29. The business had revenue of $872.30 million during the quarter, compared to analyst estimates of $839.98 million. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. The firm’s revenue was up 13.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.84 earnings per share. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. On average, sell-side analysts forecast that West Pharmaceutical Services will post 8.93 earnings per share for the current fiscal year.

West Pharmaceutical Services News Summary

Here are the key news stories impacting West Pharmaceutical Services this week:

Positive Sentiment: West posted a strong second quarter, with adjusted EPS of $2.37 and revenue of $872.3 million, both above expectations. The company also raised full-year 2026 EPS guidance and gave third-quarter guidance that topped consensus, which supports the longer-term outlook. West Reports Second-Quarter 2026 Results
Positive Sentiment: Demand remains strong for high-value injectable drug components, including products tied to GLP-1 and biologics markets, which helped drive the beat and the higher outlook. Reuters article on raised forecast
Neutral Sentiment: Investors may be taking profits after the stock’s sharp earnings-driven surge in the prior session, especially since there was no major new negative company announcement or filing behind today’s weakness. Quiver Quantitative article
Neutral Sentiment: Recent insider sales from two executives may add a small overhang, but the activity is limited and does not appear to be the main driver of the stock’s move. Insider trading details

West Pharmaceutical Services Company Profile

(Get Free Report)

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.